Brief: Hansa Biopharma Recognizes Write-Up Of SEK 1.430 Bln Related To Idefirix

Hansa Biopharma AB

04/07/2023 11:18

July 4 (Reuters) - Hansa Biopharma AB  HNSA.ST :
    * HANSA BIOPHARMA AB RECOGNIZES A WRITE-UP OF SEK 1.430
BILLION IN
INTANGIBLE ASSETS RELATED TO IDEFIRIX IN THE FINANCIAL
STATEMENTS OF THE PARENT COMPANY - NO IMPACT ON THE CONSOLIDATED
FINANCIALS
    * WRITE-UP RELATES TO IDEFIRIX
    * AFTER WRITE-UP, ASSET WILL HAVE A GROSS VALUE OF 1.500
BILLION
SEK IN FINANCIAL STATEMENTS OF HANSA BIOPHARMA
    * WRITE-UP WILL INCREASE RESTRICTED SHAREHOLDER EQUITY IN
HANSA
BIOPHARMA AB BY SEK 1.430 BILLION
    * INTANGIBLE ASSET WILL BE SUBJECT TO REGULAR AMORTIZATION
OVER
ITS USEFUL LIFE, CURRENTLY EXPECTED TO BE AT LEAST 10 YEARS
    * AS A RESULT OF RECOGNIZING DEFERRED TAX LIABILITY HANSA
HAS
RECOGNIZED A DEFERRED TAX ASSET OF SEK 0.295 BILLION THROUGH
PROFIT OR LOSS, INCREASING UNRESTRICTED SHAREHOLDER EQUITY,
RELATED TO PREVIOUSLY UNRECOGNIZED TAX LOSSES

Source text for Eikon:  ID:nWkr26YH5Y 
Further company coverage:  HNSA.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))